Calithera Biosciences Inc. (CALA) 16.42 $CALA 3 Stocks

New Post Public Reply Private Reply Replies (0) Message Board

Mar 30, 2015 at 5:33 PM

Calithera Biosciences Inc. (CALA) 16.42 $CALA

3 Stocks Breaking Out on Unusual Volume
at The Street - Fri Mar 27, 12:56PM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
SWKS: 100.13 (+1.30), AXLL: 46.85 (+0.22), CALA: 16.42 (-1.03)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 11:45AM CDT

DHRM: 2.70 (-0.10), GGB: 3.19 (+0.13), BMRN: 129.13 (+0.35), OLN: 32.41 (+1.41), HCHC: 11.35 (-0.58), APDN: 2.70 (unch), ZQK: 1.91 (+0.01), OXM: 72.16 (+1.36), ROLL: 75.53 (-0.05), GVP: 1.56 (-0.04), MOLG: 2.23 (-0.11), CCIH: 9.92 (-0.38), GBSN: 2.44 (-0.29), EVAR: 4.06 (+0.06), LIME: 3.40 (-0.16), CALA: 16.42 (-1.03), OHRP: 2.81 (+0.07), INPH: 1.47 (-0.27), CARV: 5.01 (-0.54), GNI: 8.38 (-0.65)

Calithera Biosciences (CALA) Crumbles: Stock Falls by 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 7:55AM CDT
Calithera Biosciences saw a big move last session, as the company’s shares fell by 7%. This reverses the recent trend for CALA as the stock is now up around 22%
LCI: 67.86 (+2.35), CALA: 16.42 (-1.03)

Calithera Biosciences reports FQ4 results
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:22PM CDT

CALA: 16.42 (-1.03)

Calithera Biosciences Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 26, 3:05PM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today its financial results for the fiscal fourth quarter and year ended December 31, 2014. As of December 31, 2014, cash and cash equivalents totaled $102.0 million.
CALA: 16.42 (-1.03)

Pre-Earnings Calithera Biosciences Inc. Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Thu Mar 26, 6:00AM CDT
Calithera Biosciences Inc. (NASDAQ: CALA) based in San Francisco, CA a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer will be reporting fourth quarter and year-end earnings this morning. Anticipation of this release has driven the recent investor interest in the shares of Calithera. Rollercoaster - like activity was observed for the past 4 trading days.
CALA: 16.42 (-1.03)

Calithera Biosciences (CALA) Jumps: Stock Rises 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 7:51AM CDT
Calithera Biosciences, Inc. (CALA) was a big mover last session, as the company saw its shares rise roughly 19% on the day.
LCI: 67.86 (+2.35), CALA: 16.42 (-1.03)

Calithera Biosciences to Report Fourth Quarter and Year-End 2014 Financial Results on Thursday, March 26, 2015
GlobeNewswire - Fri Mar 20, 7:30AM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company's fourth quarter and year-end 2014 financial results will be released on Thursday, March 26, 2015. Company management will host a conference call on Thursday, March 26, 2015 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
CALA: 16.42 (-1.03)

Calithera Biosciences Announces Five Data Presentations at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Wed Mar 18, 3:30PM CDT
Calithera Biosciences, Inc. (Nasdaq:CALA) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced the upcoming presentation of five preclinical abstracts, highlighting the potential of CB-839, the Company's novel, orally bioavailable glutaminase inhibitor, at the American Association for Cancer Research, taking place April 18-22, 2015 in Philadelphia, Pennsylvania. Details for the two oral presentations and three poster presentations are as follows:
CALA: 16.42 (-1.03)

Calithera Biosciences (CALA) Jumps: Stock Moves Up 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 09, 7:51AM CDT
Calithera Biosciences, Inc. (CALA) was a big mover last session, as the company saw its shares rise over 10% on the day.
LCI: 67.86 (+2.35), CALA: 16.42 (-1.03)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 8:15AM CST

NGL: 26.08 (-0.40), FNSR: 21.60 (+0.63), SSH: 4.16 (-0.02), YY: 53.99 (-1.21), CNAT: 7.53 (-0.22), ASTI: 1.20 (unch), CLDN: 21.67 (+0.58), AXN: 1.70 (-0.12), VMEM: 3.76 (+0.08), BLRX: 2.16 (+0.01), GENE: 4.95 (+1.25), OREX: 7.75 (+0.21), SKUL: 11.30 (+0.45), CALA: 16.42 (-1.03), AVEO: 1.44 (+0.07), MSO: 6.38 (-0.08), GALE: 1.41 (+0.06), CKP: 10.86 (+0.16)

Calithera Bio up big premarket on development deal
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 7:25AM CST

CALA: 16.42 (-1.03)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 4:37PM CST

FNSR: 21.60 (+0.63), POWR: 12.50 (+0.30), YY: 53.99 (-1.21), CNAT: 7.53 (-0.22), CALA: 16.42 (-1.03), MSO: 6.38 (-0.08), PRTA: 39.37 (+1.53), VMEM: 3.76 (+0.08), CKP: 10.86 (+0.16), ERII: 2.59 (-0.05)

Calithera Bio inks development deal for cancer drug candidates
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 4:32PM CST

CALA: 16.42 (-1.03)

Calithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February
GlobeNewswire - Tue Feb 03, 8:00AM CST
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation in two investor conferences during the month of February.
CALA: 16.42 (-1.03)

Calithera Biosciences Appoints Keith Orford, M.D., Ph.D. to Vice President of Clinical Development
GlobeNewswire - Fri Jan 30, 9:40AM CST
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today the appointment of Dr. Keith Orford, M.D. Ph.D., as Vice President of Clinical Development. He joins the company following a distinguished career in oncology pharmaceuticals development, including senior clinical roles with GlaxoSmithKline (GSK) and Merck. At Calithera, Dr. Orford will be responsible for clinical development of CB-839, its lead oral product candidate in tumor metabolism, as well as subsequent clinical development programs.
CALA: 16.42 (-1.03), GSK: 47.20 (+0.18)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Marshall Goldman Expands Footprint with Marino Acquisition

Revving Up in Florida: Marshall Goldman's Strategic Leap If you're tuned into the luxury car scene, you probably already heard Marshall Goldman is making moves into Florida. Buying Marino Performance Motors of West Palm Beach isn't just another notch on their belt—it's a strategic leap into their second-largest market. This ain't merely about showroom floor space. Think...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

JiMMYBAR! Unveils World's First Creatine Trail Mix

The New Face of Snacking: Creatine Trail Mix I'll tell you right off the bat, JiMMYBAR! seems to be cornering the snack world with an odd—but interesting—twist. They've just launched the world's first Creatine + Protein Trail Mix, blending muscle-building nutrients with the classic crunch of trail mix. Sounds quirky, and it’s exclusive to their site, JiMMYBARs.com....

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...